Author

H. Shirley

Observed names: H Shirley, Helen Shirley

Institutions: The University of Melbourne, St John of God Health Care

Observed institutions: Cedars-Sinai Medical Center, The University of Sydney, Mayo Clinic, The University of Melbourne, King Edward Memorial Hospital, Westmead Hospital, Women and Infants Research Foundation, Westmead Institute for Medical Research, St John of God Health Care

OpenAlex ID: A5111669345

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

2018 · Olga Kondrashova, Monique Topp, et al. · Nature Communications · 296

Prognostic gene expression signature for high-grade serous ovarian cancer

2020 · J. Millstein, T. Budden, et al. · Annals of Oncology · 155

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

2020 · Eun Young Kang, Dane Cheasley, et al. · Modern Pathology · 42

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

2024 · Ksenija Nesic, John J. Krais, et al. · Molecular Cancer · 36

Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer

2014 · Bo Gao, Amanda Russell, et al. · Scientific Reports · 36

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

2018 · Matthew S. Block, Robert A. Vierkant, et al. · Mayo Clinic Proceedings · 31

Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer

2024 · Nikki L. Burdett, Madelynne O. Willis, et al. · Nature Communications · 16

Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer

2023 · Nikki L. Burdett, Madelynne O. Willis, et al. · Scientific Reports · 6

Works count: 9

Citation count: 629

H-index: 8

I10-index: 8